Active substance |
ataluren |
Holder |
PTC Therapeutics France |
Status |
Running |
Indication |
Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, inambulatory patients aged 5 years and older for patients who have been treated with this medicinal product as part of the clinical trials (studies 019 and 020E) that are currently in the close-out process. |
Public documents |
|
Dernière mise à jour |
15/09/2017 |
Translarna®
Last updated on 13/02/2024